{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix J:', 'Psoriasis Area Severity Index (PASI)', '* Round all calculations to 1 decimal place.', 'STEP A. Please write in the appropriate number for rows 1 - 3 using the scale', 'below:', '0 = None 1 = Slight 2 = Moderate 3 = Severe 4 = Very Severe', 'UPPER', 'LOWER', 'HEAD', 'TRUNK', 'LIMBS', 'LIMBS', '1. Erythema', '2. Thickness', '3. Scaling', '4. TOTAL Each Column', 'STEP B. Enter the number of hands the psoriasis covers on each body area', 'UPPER', 'LOWER', 'HEAD', 'TRUNK', 'LIMBS', 'LIMBS', '5. Number of Hands', '6. Area (% of total BSA)', '10', '30', '20', '40', 'STEP C. Calculate % of involvement:', '7. % of each region involved [(Row 5 1/6 Row 6) x', '100*', '8. TOTAL BSA (sum of # of hands from row 5)', 'STEP D. Select Degree of Involvement using value in Row 7:', '0 = No involvement', '1 = <10%', '2 = 10 < 30%', '3 = 30 < 50%', '4 = 50 < 70%', '5 = 70 < 90%', '6 = 90 < 100%', '9. Degree of Involvement (0-6) of each region', 'STEP E. Calculate PASI (Row 4 x Row 6 x Row 9) / 100*', '10. PASI for each body region', '11. TOTAL PASI (sum of Row 10 subscores)', 'Source: Fredriksson, 1978.', 'Confidential and Proprietary', '84', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Appendix K: Patient Needs Questionnaire (PNQ)', \"With the help of the following questions, we'd like to know how important the below mentioned\", 'goals are to you personally in the current treatment of your skin disease.', 'For each of the following statements, please mark how important this treatment goal is to you.', 'If a statement does not apply to you, e.g. because you do not have pain, please mark \"does not', 'apply to me\".', 'As a result of therapy, how important is it for you to', '1', 'be free of pain', 'O', 'O', 'O', 'O', 'O', 'O', '2', 'be free of itching', 'O', 'O', 'O', 'O', 'O', 'O', '3', 'no longer have burning sensations on your skin', 'O', 'O', 'O', 'O', 'O', 'O', '4', 'be healed of all skin defects', 'O', 'O', 'O', 'O', 'O', 'O', '5', 'be able to sleep better', 'O', 'O', 'O', 'O', 'O', 'O', '6', 'feel less depressed', 'O', 'O', 'O', 'O', 'O', 'O', '7', 'experience a greater enjoyment of life', 'O', 'O', 'O', 'O', 'O', 'O', '8', 'have no fear that the disease will become worse', 'O', 'O', 'o', 'O', 'O', 'O', '9', 'be able to lead a normal everyday life', 'O', 'O', 'O', 'O', 'O', 'O', '10', 'be more productive in everyday life', 'O', 'O', 'O', 'O', 'O', 'O', '11', 'be less of a burden to relatives and friends', 'O', 'O', 'O', 'o', 'O', 'O', '12', 'be able to engage in normal leisure activities', 'O', 'O', 'O', 'O', 'O', 'O', '13', 'be able to lead a normal working life', 'O', 'O', 'O', 'O', 'O', 'O', '14', 'be able to have more contact with other people', 'O', 'O', 'O', 'o', 'o', 'O', '15', 'be comfortable showing yourself more in public', 'O', 'O', 'O', 'O', 'O', 'O', '16', 'be less burdened in your partnership', 'O', 'O', 'O', 'O', 'O', 'O', '17', 'be able to have a normal sex life', 'o', 'o', 'o', 'O', 'o', 'o', '18', 'be less dependent on doctor and clinic visits', 'O', 'O', 'O', 'O', 'O', 'O', '19', 'need less time for daily treatment', 'O', 'O', 'O', 'O', 'O', 'O', '20', 'have fewer out-of-pocket treatment expenses', 'o', 'o', 'o', 'o', 'o', 'o', '21', 'have fewer side effects', 'O', 'O', 'O', 'O', 'O', 'O', '22', 'find a clear diagnosis and therapy', 'O', 'O', 'O', 'O', 'O', 'O', '23', 'have confidence in the therapy', 'O o o o o', 'O', '24', 'get better skin quickly', 'O', 'O', 'O', 'O', 'O', 'O', '25', 'regain control of the disease', 'O', 'O', 'O', 'O', 'O', 'O', 'Confidential and Proprietary', '85', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}